Bayer`s patent for blood thinner Xarelto invalid, UK court rules
MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in EuropeAdditional manufacturing area of 3,000m2...
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
Sandoz wins FDA approval for first two biosimilars for Amgen`s bone drug
Sandoz announces nominations to the Board of Directors and leadership change
Sandoz receives FDA approval for first and only denosumab biosimilars
Sandoz`s Biologic Jubbonti (denosumab-bbdz) Receives Approval in the U.S.
Sandoz acquires CIMERLI® business from Coherus
Sandoz US subsidiaries resolve generic drug antitrust class action litigation
Sandoz enters $265 mln settlement agreement in U.S. price-fixing case